Pulmatrix Interest Expense 2011-2026 | PULM

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Pulmatrix

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-204 K	-196 K	-248 K	-198 K	-11 K	-239 K	-5 K	186 K	643 K	881 K	953 K	15.3 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
15.3 M	-248 K	1.4 M

Quarterly Interest Expense Pulmatrix

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-41 K	-43 K	-80 K	-	-31 K	-43 K	-82 K	-	-52 K	-61 K	-85 K	-	-54 K	-51 K	-11 K	-	5 K	2 K	-22 K	-	-10 K	-9 K	-1 K	-	-2 K	1 K	-3 K	106 K	186 K	80 K	106 K	-	153 K	172 K	187 K	-	225 K	224 K	223 K	-	220 K	327 K	184 K	-	7.88 M	5.61 M	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.88 M	-85 K	423 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	722 K	-	-	$ 866 M	China
Apellis Pharmaceuticals APLS	-133 K	$ 20.36	-1.64 %	$ 2.57 B	USA
Axsome Therapeutics AXSM	-15.9 M	$ 164.62	-1.06 %	$ 8.19 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.74	-2.23 %	$ 1.12 B	Canada
Certara CERT	6.34 M	$ 7.27	3.05 %	$ 1.17 B	USA
Catalyst Pharmaceuticals CPRX	25.7 M	$ 23.94	0.23 %	$ 2.93 B	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 17.89	-1.43 %	$ 459 M	USA
Exelixis EXEL	-198 K	$ 40.99	-0.1 %	$ 11.1 B	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	399 K	$ 26.27	-2.2 %	$ 703 M	USA
Galapagos NV GLPG	911 K	$ 33.2	-2.61 %	$ 2.69 B	Belgium
Galecto GLTO	1.69 M	$ 29.63	-1.39 %	$ 787 M	Danmark
Codexis CDXS	-10.4 M	$ 1.0	-1.47 %	$ 73.4 M	USA
Halozyme Therapeutics HALO	21.5 M	$ 69.4	-0.64 %	$ 8.32 B	USA
Hoth Therapeutics HOTH	27.1 K	$ 1.01	-0.98 %	$ 6.44 M	USA
Harmony Biosciences Holdings HRMY	-680 K	$ 28.63	-0.95 %	$ 1.65 B	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
ImmuCell Corporation ICCC	349 K	$ 6.3	-3.67 %	$ 51.5 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Immunic IMUX	5.02 M	$ 1.12	5.19 %	$ 174 M	USA
Agenus AGEN	1.26 M	$ 3.24	-3.14 %	$ 1.16 M	USA
Immunovant IMVT	471 K	$ 27.24	-1.84 %	$ 4.13 B	USA
Inhibrx INBX	-580 K	$ 76.35	-1.47 %	$ 3.6 B	USA
InMed Pharmaceuticals INM	431 K	$ 0.78	-4.88 %	$ 1.91 M	Canada
INmune Bio INMB	2.28 M	$ 1.39	4.66 %	$ 25 M	USA
Insmed Incorporated INSM	83.8 M	$ 147.23	0.62 %	$ 29.3 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA